Tremelimumab + Durvalumab + Gemcitabine + Cisplatin
Phase 2Recruiting 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Combined Hepatocellular and Cholangiocarcinoma
Conditions
Combined Hepatocellular and Cholangiocarcinoma
Trial Timeline
Mar 1, 2026 → Apr 1, 2027
NCT ID
NCT06855225About Tremelimumab + Durvalumab + Gemcitabine + Cisplatin
Tremelimumab + Durvalumab + Gemcitabine + Cisplatin is a phase 2 stage product being developed by AstraZeneca for Combined Hepatocellular and Cholangiocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06855225. Target conditions include Combined Hepatocellular and Cholangiocarcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06855225 | Phase 2 | Recruiting |
Competing Products
6 competing products in Combined Hepatocellular and Cholangiocarcinoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pravafen + Pravastatin + Fenofibrate | Shionogi | Phase 3 | 77 |
| zonisamide | Eisai | Pre-clinical | 23 |
| Dalpicilib + Abiraterone Acetate (II) + Androgen Deprivation Therapy + Prednisone | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Vaxelis™ | Merck | Approved | 85 |
| Leios/Alesse | Pfizer | Pre-clinical | 22 |
| Sodium phenylbutyrate | Zevra Therapeutics | Phase 1 | 25 |